GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (FRA:ILA) » Definitions » 3-Year Revenue Growth Rate

Imugene (FRA:ILA) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Imugene 3-Year Revenue Growth Rate?

Imugene's Revenue per Share for the six months ended in Dec. 2024 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Imugene's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Imugene's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imugene's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Imugene's 3-Year Revenue Growth Rate falls into.


;
;

Imugene 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Imugene  (FRA:ILA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Imugene 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Imugene's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Imugene Business Description

Industry
Traded in Other Exchanges
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines